EoP Biomarker Blood Assay for Non-Invasive EoE Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and monitoring eosinophilic esophagitis (EoE) rely on invasive serial endoscopies with esophageal biopsies, necessitating a need for less-invasive blood-based biomarkers to evaluate EoE disease activity effectively.
Innovation Solution
Elevated levels of eosinophil lineage-committed progenitor (EoP) in blood samples are used to diagnose active or inactive EoE, with specific cut-off values determining disease status, and a kit is provided for assaying EoP levels to facilitate diagnosis and treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive serial endoscopies with esophageal biopsies are used to diagnose and monitor EoE, then measurement precision of esophageal eosinophil counts is improved, but ease of operation and patient comfort deteriorate
Solution Approach 1:
The patent introduces eosinophil progenitor (EoP) cells in peripheral blood as an intermediary biomarker that correlates with esophageal eosinophil infiltration. Instead of directly measuring esophageal tissue eosinophils through invasive biopsies, the method measures EoP levels in easily obtainable blood samples, which serve as a surrogate indicator of disease activity
Solution Approach 2:
The patent replaces the mechanical invasive procedure of endoscopy and biopsy with a simple blood draw and laboratory analysis of EoP levels. This substitution eliminates the need for complex endoscopic equipment and invasive tissue sampling while maintaining diagnostic capability
2Reliability
If invasive endoscopic procedures are performed serially to monitor EoE treatment efficacy, then reliability of disease activity assessment is improved, but loss of time and patient burden increase
Solution Approach 1:
The patent enables continuous monitoring of EoE disease activity through repeated blood draws at convenient intervals, allowing treatment efficacy to be assessed over time without the logistical constraints of scheduling multiple endoscopic procedures. The blood-based EoP measurement can be performed serially with minimal disruption to patient life
3Ease of operation
If blood-based biomarkers are developed to evaluate EoE disease activity, then ease of operation and patient comfort are improved, but measurement precision and reliability may deteriorate
Solution Approach 1:
The patent identifies and measures specific parameters (EoP cell levels, CD34+CD38+CD125+ phenotype) in peripheral blood that have been shown to correlate with esophageal eosinophil infiltration. By focusing on these specific cellular parameters rather than general blood counts, the method achieves both ease of sampling and diagnostic precision
Solution Approach 2:
The patent replaces direct tissue measurement with a surrogate blood-based measurement system. The EoP cells in peripheral blood serve as a proxy indicator that reflects the pathological process in the esophagus, allowing indirect but accurate assessment of disease activity through easily obtainable blood samples
Data Source
AI summary
Disclosed are methods of diagnosing and treating a subject with active or inactive eosinophilic esophagitis (EoE). The methods may include the steps of detecting whether a level of eosinophil lineage-committed progenitor (EoP) is elevated in a blood sample obtained from a subject, diagnosing the subject with active EoE when an EoP level in the sample is elevated above a pre-determined cut-off value and diagnosing the subject with inactive EoE when the EoP level in the sample is below a pre-determined cut-off value; and treating the subject diagnosed with active EoE. Kits related to same are also disclosed.